The BRAF mutation causes both ab initio resistance to imatinib treatment [19, 22] and secondary resistance when it occurs as a secondary event in KIT/PDGFRA-mutated GIST relapsing under therapy [19, 23]. Here, PDGFRA is linked to gastrointestinal stromal tumor.